Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;50(3):333-340.
doi: 10.1007/s00240-022-01317-2. Epub 2022 Feb 24.

Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers

Matthias B Moor  1   2 , Nasser A Dhayat  3   4 , Simeon Schietzel  3   4 , Michael Grössl  3   4 , Bruno Vogt  3   4 , Daniel G Fuster  3   4
Affiliations

Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers

Matthias B Moor et al. Urolithiasis. 2022 Jun.

Abstract

The spectrum of diseases with overactive renin-angiotensin-aldosterone system (RAS) or elevated circulating FGF23 overlaps, but the relationship between aldosterone and FGF23 remains unclarified. Here, we report that systemic RAS activation sensitively assessed by urinary tetrahydroaldosterone excretion is associated with circulating C-terminal FGF23. We performed a retrospective analysis in the Bern Kidney Stone Registry, a single-center observational cohort of kidney stone formers. Urinary excretion of the main aldosterone metabolite tetrahydroaldosterone was measured by gas chromatography-mass spectrometry. Plasma FGF23 concentrations were measured using a C-terminal assay. Regression models were calculated to assess the association of plasma FGF23 with 24 h urinary tetrahydroaldosterone excretion. We included 625 participants in the analysis. Mean age was 47 ± 14 years and 71% were male. Mean estimated GFR was 94 ml/min per 1.73 m2. In unadjusted analyses, we found a positive association between plasma FGF23 and 24 h urinary tetrahydroaldosterone excretion (β: 0.0027; p = 4.2 × 10-7). In multivariable regression models adjusting for age, sex, body mass index and GFR, this association remained robust (β: 0.0022; p = 2.1 × 10-5). Mineralotropic hormones, 24 h urinary sodium and potassium excretion as surrogates for sodium and potassium intake or antihypertensive drugs did not affect this association. Our data reveal a robust association of RAS activity with circulating FGF23 levels in kidney stone formers. These findings are in line with previous studies in rodents and suggest a physiological link between RAS system activation and FGF23 secretion.

Keywords: Aldosterone; FGF23; Renin–angiotensin system; Steroid metabolite; Tetrahydroaldosterone.

PubMed Disclaimer

Conflict of interest statement

DGF has served as a consultant for Otsuka Pharmaceuticals and Alnylam, and has received unrestricted research funding from Novartis, Abbvie, Otsuka Pharmaceuticals and Boehringer Ingelheim.

Figures

Fig. 1
Fig. 1
Association of urinary tetrahydroaldosterone with plasma FGF23 in kidney stone formers. A and B display visualizations of a multivariable linear model in which urinary tetrahydroaldosterone (µg/24 h) associated with log-transformed FGF23 [log FGF23 RU/mL]. The model was adjusted for age, sex, eGFR and BMI. B depicts individual regression lines for each sex separately. Color-shaded areas indicate 95% confidence intervals
Fig. 2
Fig. 2
Association of 24 h urinary sodium and potassium with 24 h urinary tetrahydroaldosterone excretion. Univariable association between urinary (A) sodium and B potassium excretion (mmol/24 h) and urinary excretion of tetrahydroaldosterone (µg/24 h). Gray shaded areas represent 95% confidence intervals
See this image and copyright information in PMC

References

    1. de Seigneux S, Martin P-Y. Phosphate and FGF23 in the renoprotective benefit of RAAS inhibition. Pharmacol Res. 2016;106:87–91. doi: 10.1016/j.phrs.2016.02.015. - DOI - PubMed
    1. Imazu M, Takahama H, Asanuma H, Funada A, Sugano Y, Ohara T, Hasegawa T, Asakura M, Kanzaki H, Anzai T, Kitakaze M. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. Am J Physiol Heart Circ Physiol. 2014;307:H1504–1511. doi: 10.1152/ajpheart.00331.2014. - DOI - PubMed
    1. Akhabue E, Vu T-HT, Vaidya A, Michos ED, de Boer IH, Kestenbaum B, Allison M, Szklo M, Ouyang P, Yancy CW, Wolf M, Isakova T, Carnethon MR. Fibroblast growth factor-23, heart failure risk, and renin-angiotensin-aldosterone-system blockade in hypertension: the MESA study. Am J Hypertens. 2019;32:18–25. doi: 10.1093/ajh/hpy142. - DOI - PMC - PubMed
    1. Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, de Borst MH. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol. 2018;253:84–90. doi: 10.1016/j.ijcard.2017.10.010. - DOI - PubMed
    1. Humalda JK, Riphagen IJ, Assa S, Hummel YM, Westerhuis R, Vervloet MG, Voors AA, Navis G, Franssen CFM, de Borst MH, NIGRAM Consortium Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc-Eur Ren Assoc. 2016;31:1494–1501. doi: 10.1093/ndt/gfv393. - DOI - PubMed